Ubs Group Ag Biodesix Inc Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Biodesix Inc stock. As of the latest transaction made, Ubs Group Ag holds 2,266 shares of BDSX stock, worth $1,926. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,266

Previous 250 806.4%

Holding current value

$1,926

Previous $0 Infinity%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.16 - $1.76 $2,338 - $3,548	2,016 Added 806.4%	2,266 $3,000
Q3 2024 Nov 14, 2024	SELL	$1.53 - $1.96 $2,806 - $3,594	-1,834 Reduced 88.0%	250 $0
Q2 2024 Aug 13, 2024	BUY	$1.21 - $1.71 $2,521 - $3,563	2,084 New	2,084 $3,000
Q3 2023 Nov 09, 2023	BUY	$1.04 - $1.74 $2,644 - $4,424	2,543 Added 1695.33%	2,693 $4,000
Q1 2023 May 12, 2023	SELL	$1.52 - $2.5 $6,412 - $10,547	-4,219 Reduced 96.57%	150 $0
Q4 2022 Feb 08, 2023	BUY	$0.98 - $2.3 $4,134 - $9,703	4,219 Added 2812.67%	4,369 $10,000
Q3 2022 Nov 10, 2022	SELL	$1.24 - $2.89 $5,050 - $11,770	-4,073 Reduced 96.45%	150 $0
Q2 2022 Aug 10, 2022	BUY	$1.32 - $2.12 $4,944 - $7,941	3,746 Added 785.32%	4,223 $7,000
Q1 2022 May 16, 2022	SELL	$1.69 - $5.81 $5,751 - $19,771	-3,403 Reduced 87.71%	477 $1,000
Q4 2021 Feb 14, 2022	BUY	$4.09 - $8.67 $15,255 - $32,339	3,730 Added 2486.67%	3,880 $21,000
Q3 2021 Nov 15, 2021	SELL	$6.6 - $12.78 $18,631 - $36,077	-2,823 Reduced 94.95%	150 $1,000
Q2 2021 Aug 13, 2021	BUY	$12.14 - $20.35 $32,450 - $54,395	2,673 Added 891.0%	2,973 $39,000
Q1 2021 May 12, 2021	SELL	$16.87 - $31.21 $27,548 - $50,965	-1,633 Reduced 84.48%	300 $6,000
Q4 2020 Feb 11, 2021	BUY	$10.89 - $20.16 $21,050 - $38,969	1,933 New	1,933 $39,000

Others Institutions Holding BDSX

# of Institutions

Shares Held

56.3M

Call Options Held

342K

Put Options Held

10.1K

View Full List

About BIODESIX INC

Ticker BDSX
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 39,982,000
Market Cap $34M
Description
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pat...

More about BDSX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account